ASH 2017: ADCT-402, A CD19-Directed mAB, Shows Encouraging Early Results in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Only registered members have full access to PracticeUpdate content.